198 related articles for article (PubMed ID: 34302033)
21. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
[TBL] [Abstract][Full Text] [Related]
22. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
23. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
[TBL] [Abstract][Full Text] [Related]
24. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract][Full Text] [Related]
26. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
27. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
28. The landscape of genomic alterations across childhood cancers.
Gröbner SN; Worst BC; Weischenfeldt J; Buchhalter I; Kleinheinz K; Rudneva VA; Johann PD; Balasubramanian GP; Segura-Wang M; Brabetz S; Bender S; Hutter B; Sturm D; Pfaff E; Hübschmann D; Zipprich G; Heinold M; Eils J; Lawerenz C; Erkek S; Lambo S; Waszak S; Blattmann C; Borkhardt A; Kuhlen M; Eggert A; Fulda S; Gessler M; Wegert J; Kappler R; Baumhoer D; Burdach S; Kirschner-Schwabe R; Kontny U; Kulozik AE; Lohmann D; Hettmer S; Eckert C; Bielack S; Nathrath M; Niemeyer C; Richter GH; Schulte J; Siebert R; Westermann F; Molenaar JJ; Vassal G; Witt H; ; ; Burkhardt B; Kratz CP; Witt O; van Tilburg CM; Kramm CM; Fleischhack G; Dirksen U; Rutkowski S; Frühwald M; von Hoff K; Wolf S; Klingebiel T; Koscielniak E; Landgraf P; Koster J; Resnick AC; Zhang J; Liu Y; Zhou X; Waanders AJ; Zwijnenburg DA; Raman P; Brors B; Weber UD; Northcott PA; Pajtler KW; Kool M; Piro RM; Korbel JO; Schlesner M; Eils R; Jones DTW; Lichter P; Chavez L; Zapatka M; Pfister SM
Nature; 2018 Mar; 555(7696):321-327. PubMed ID: 29489754
[TBL] [Abstract][Full Text] [Related]
29. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
30. Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors.
Yang Z; Cui W; Yu R; Dong X; Zhao J; Dai L; Ou Q; Bao H; Wu X; Wu C; Lai J
Front Oncol; 2022; 12():753311. PubMed ID: 35402276
[TBL] [Abstract][Full Text] [Related]
31. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract][Full Text] [Related]
32. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
33. [CUP syndrome: molecular pathogenesis and biology].
Krämer A; Gattenlöhner S; Neben K
Pathologe; 2009 Mar; 30(2):117-24. PubMed ID: 19132375
[TBL] [Abstract][Full Text] [Related]
34. The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.
Lombardo R; Tosi F; Nocerino A; Bencardino K; Gambi V; Ricotta R; Spina F; Siena S; Sartore-Bianchi A
Front Oncol; 2020; 10():533. PubMed ID: 32457826
[No Abstract] [Full Text] [Related]
35. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.
Möhrmann L; Werner M; Oleś M; Mock A; Uhrig S; Jahn A; Kreutzfeldt S; Fröhlich M; Hutter B; Paramasivam N; Richter D; Beck K; Winter U; Pfütze K; Heilig CE; Teleanu V; Lipka DB; Zapatka M; Hanf D; List C; Allgäuer M; Penzel R; Rüter G; Jelas I; Hamacher R; Falkenhorst J; Wagner S; Brandts CH; Boerries M; Illert AL; Metzeler KH; Westphalen CB; Desuki A; Kindler T; Folprecht G; Weichert W; Brors B; Stenzinger A; Schröck E; Hübschmann D; Horak P; Heining C; Fröhling S; Glimm H
Nat Commun; 2022 Aug; 13(1):4485. PubMed ID: 35918329
[TBL] [Abstract][Full Text] [Related]
36. [New strategies for the treatment of carcinoma of unknown primary].
Li LX; Zhang D; Ma F
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):44-49. PubMed ID: 36709119
[TBL] [Abstract][Full Text] [Related]
37. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Pentheroudakis G; Kotteas EA; Kotoula V; Papadopoulou K; Charalambous E; Cervantes A; Ciuleanu T; Fountzilas G; Pavlidis N
Clin Exp Metastasis; 2014 Oct; 31(7):761-9. PubMed ID: 24997156
[TBL] [Abstract][Full Text] [Related]
38. Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
van Mourik A; Tonkin-Hill G; O'Farrell J; Waller S; Tan L; Tothill RW; Bowtell D; Fox S; Fellowes A; Fedele C; Schofield P; Sivakumaran T; Wong HL; Mileshkin L
Br J Cancer; 2023 Aug; 129(2):301-308. PubMed ID: 37225894
[TBL] [Abstract][Full Text] [Related]
39. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
40. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
